Skip to main content

NABP Acquires Patient Safety Tool From Chronicled, Inc.

MOUNT PROSPECT, IL, June 14, 2023 (GLOBE NEWSWIRE) — The National Association of Boards of Pharmacy® (NABP®) announced today that it acquired the MediLedger Product Verification System (PVS) from Chronicled, Inc. The Association purchased the PVS to enable trading partners and regulators to conduct product verification, when required by the Drug Supply Chain Security Act (DSCSA), for use in its new product, Pulse by NABP™.

Since launching the PVS in 2019, Chronicled has used its blockchain-powered MediLedger Network to make life sciences more accurate, efficient​,​ and aligned across the industry. The PVS has assisted members of the supply chain in complying with DSCSA, and it will continue to provide this assistance when Pulse launches this summer.

Pulse is the Association’s inclusive, accessible​,​ and secure digital platform that connects regulators and members of the supply chain and simplifies DSCSA compliance. Through Pulse, the PVS for manufacturers, distributors, and solution providers will continue to be offered as a cost-effective global trade item number directory for saleable-returns verification by solution providers and trading partners. Recognizing the importance of Verification Router Service (VRS) in keeping the supply chain safe, NABP plans to help grow existing industry adoption of VRS by expanding access to such verification tools for state regulators and the dispensers they regulate. In addition, NABP remains committed to following GS1 standards and the Partnership for DSCSA Governance’s guiding blueprint as adopted by the industry. 

“The PVS has been, and will remain, a critical tool to assist members of the prescription drug supply chain with compliance with DSCSA and to protect patients from counterfeit or substandard prescription medications,” Vinod Lakhani, chief executive officer of Chronicled, said. “With full implementation of DSCSA on the horizon, Chronicled believes that transitioning stewardship of PVS to NABP will take the PVS to even greater heights as a valuable tool to keep patients safe. We are thrilled to see our technology platform continue to make an impact in the industry. This transition allows us to double down on our commitment to our customers by enhancing and scaling the Contracts & Chargebacks solution on the MediLedger Network.” 

“Chronicled has built an incredible foundation with PVS​.​ NABP believes we are well positioned to continue its growth by integrating the solution seamlessly into Pulse, which will equip state regulators and all members of the supply chain with the critical tools they need to protect our nation’s patients from counterfeit medications,” said NABP Executive Director/Secretary Lemrey “Al” Carter, PharmD, MS, RPh.

To learn more about how Pulse simplifies DSCSA compliance while furthering NABP’s mission of protecting public health, visit https://pulse.pharmacy.   

-30- 

About Chronicled, Inc. 

The MediLedger Network is an industry-led, blockchain-powered network within the life sciences industry. Chronicleds role is to provide administration and build solutions on top of the MediLedger Network to facilitate alignment and enable automation between trading partners. For more information, please visit www.chronicled.com.

About Pulse by NABP 

Pulse by NABP is an inclusive, accessible, centralized digital platform that simplifies the process of achieving DSCSA compliance. Pulse provides access to NABPs user-friendly tools and comprehensive network of relationships, enabling consistent communication with trusted, verified partners across the supply chain. 

About NABP 

NABP is the independent, international, and impartial Association that assists its member boards in protecting the public health. 

CONTACT: Larissa Doucette
847/391-4405
help@nabp.pharmacy

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.